Back to top

AstraZeneca Advances AZD5004 Combo Data With Diabetes Drugs, Offering Subtle Upside for AZN Investors

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca’s latest update covers a Phase 1 trial titled “An Open-l...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

AstraZeneca PLC (AZN)